Conference Proceedings

Expanded RAS and BRAF V600 testing as predictive biomarkers for single agent cetuximab in the randomized phase III CO.17 trial.

Jonathan M Loree, Anthony Dowers, Dongsheng Tu, Christopher J O'Callaghan, Dan Edelstein, Hannah Quinn, Derek J Jonker, Chris Karapetis, Timothy Jay Price, John Raymond Zalcberg, Malcolm J Moore, Paul Michael Waring, Hagen F Kennecke, Stanley R Hamilton, Scott Kopetz

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2019